

METABOLIC DISORDERS GENE PANEL DG 3.4.0 (723 genes)

Releasedate: 19-04-2022

| <i>Gene</i> | <i>TWIST covered >10x</i> | <i>TWIST covered >20x</i> | <i>Associated Phenotype description and OMIM disease ID</i> |
|-------------|------------------------------|------------------------------|--|
| AASS | 100,0% | 100,0% | Hyperlysinemia, 238700 |
| ABAT | 100,0% | 100,0% | GABA-transaminase deficiency, 613163 |
| ABCC8 | 100,0% | 100,0% | Diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 Diabetes mellitus, transient neonatal 2, 610374 Diabetes mellitus, noninsulin-dependent, 125853 Hypoglycemia of infancy, leucine-sensitive, 240800 Hyperinsulinemic hypoglycemia, familial, 1, 256450 |
| ABCD1 | 100,0% | 100,0% | Adrenoleukodystrophy, 300100 Adrenomyeloneuropathy, adult, 300100 |
| ABCD2 | 100,0% | 100,0% | No OMIM Disease ID |
| ABCD3 | 100,0% | 100,0% | ?Bile acid synthesis defect, congenital, 5, 616278 |
| ABCD4 | 100,0% | 100,0% | Methylmalonic aciduria and homocystinuria, cblJ type, 614857 |
| ABCG5 | 100,0% | 100,0% | Sitosterolemia 2, 618666 |
| ABCG8 | 100,0% | 100,0% | Sitosterolemia 1, 210250 |
| ABHD12 | 100,0% | 100,0% | Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 |
| ABHD5 | 100,0% | 100,0% | Chanarin-Dorfman syndrome, 275630 |
| ACACA | 100,0% | 100,0% | No OMIM Disease ID |
| ACAD8 | 100,0% | 100,0% | Isobutyryl-CoA dehydrogenase deficiency, 611283 |
| ACAD9 | 100,0% | 100,0% | Mitochondrial complex I deficiency, nuclear type 20, 611126 |
| ACADM | 100,0% | 100,0% | Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 |
| ACADS | 100,0% | 100,0% | Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 |
| ACADSB | 100,0% | 100,0% | 2-methylbutyrylglycinuria, 610006 |
| ACADVL | 100,0% | 100,0% | VLCAD deficiency, 201475 |
| ACAT1 | 100,0% | 100,0% | Alpha-methylacetoacetic aciduria, 203750 |
| ACAT2 | 100,0% | 100,0% | No OMIM Disease ID |
| ACBD5 | 100,0% | 100,0% | Retinal dystrophy with leukodystrophy, 618863 |
| ACO2 | 100,0% | 100,0% | ?Optic atrophy 9, 616289 Infantile cerebellar-retinal degeneration, 614559 |

| | | | |
|----------|--------|--------|---|
| ACOX1 | 100,0% | 100,0% | Mitchell syndrome, 618960 Peroxisomal acyl-CoA oxidase deficiency, 264470 |
| ACOX2 | 100,0% | 100,0% | Bile acid synthesis defect, congenital, 6, 617308 |
| ACSF3 | 100,0% | 100,0% | Combined malonic and methylmalonic aciduria, 614265 |
| ACSL4 | 100,0% | 100,0% | Intellectual developmental disorder, X-linked 63, 300387 |
| ACY1 | 100,0% | 100,0% | Aminoacylase 1 deficiency, 609924 |
| ADA | 100,0% | 100,0% | Adenosine deaminase deficiency, partial, 102700 Severe combined immunodeficiency due to ADA deficiency, 102700 |
| ADCK5 | 100,0% | 100,0% | No OMIM Disease ID |
| ADCY5 | 100,0% | 99,9% | Dyskinesia with orofacial involvement, autosomal dominant, 606703 Neurodevelopmental disorder with hyperkinetic movements and dyskinesia, 619651 Dyskinesia with orofacial involvement, autosomal recessive, 619647 |
| ADK | 84,5% | 84,5% | Hypermethioninemia due to adenosine kinase deficiency, 614300 |
| ADSL | 100,0% | 100,0% | Adenylosuccinase deficiency, 103050 |
| AGA | 100,0% | 100,0% | Aspartylglucosaminuria, 208400 |
| AGK | 91,2% | 91,2% | Cataract 38, autosomal recessive, 614691 Sengers syndrome, 212350 |
| AGL | 100,0% | 100,0% | Glycogen storage disease IIIa, 232400 Glycogen storage disease IIIb, 232400 |
| AGPAT2 | 100,0% | 100,0% | Lipodystrophy, congenital generalized, type 1, 608594 |
| AGPS | 100,0% | 99,9% | Rhizomelic chondrodysplasia punctata, type 3, 600121 |
| AGXT | 100,0% | 100,0% | Hyperoxaluria, primary, type 1, 259900 |
| AHCY | 100,0% | 100,0% | Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752 |
| AK1 | 100,0% | 100,0% | Hemolytic anemia due to adenylate kinase deficiency, 612631 |
| AK2 | 100,0% | 100,0% | Reticular dysgenesis, 267500 |
| AKR1C1 | 100,0% | 100,0% | No OMIM Disease ID |
| AKR1D1 | 100,0% | 100,0% | Bile acid synthesis defect, congenital, 2, 235555 |
| ALAD | 100,0% | 100,0% | Porphyria, acute hepatic, 612740 |
| ALAS2 | 100,0% | 100,0% | Anemia, sideroblastic, 1, 300751 Protoporphyrinemia, erythropoietic, X-linked, 300752 |
| ALDH18A1 | 100,0% | 100,0% | Spastic paraplegia 9A, autosomal dominant, 601162 Cutis laxa, autosomal recessive, type IIIA, 219150 Spastic paraplegia 9B, autosomal recessive, 616586 Cutis laxa, autosomal dominant 3, 616603 |
| ALDH1A3 | 100,0% | 100,0% | Microphthalmia, isolated 8, 615113 |
| ALDH2 | 100,0% | 100,0% | Alcohol sensitivity, acute, 610251 |
| ALDH3A2 | 93,2% | 93,2% | Sjogren-Larsson syndrome, 270200 |

| | | | |
|---------|--------|--------|--|
| ALDH4A1 | 100,0% | 100,0% | Hyperprolinemia, type II, 239510 |
| ALDH5A1 | 100,0% | 100,0% | Succinic semialdehyde dehydrogenase deficiency, 271980 |
| ALDH6A1 | 100,0% | 100,0% | Methylmalonate semialdehyde dehydrogenase deficiency, 614105 |
| ALDH7A1 | 100,0% | 100,0% | Epilepsy, pyridoxine-dependent, 266100 |
| ALDOA | 100,0% | 100,0% | Glycogen storage disease XII, 611881 |
| ALDOB | 100,0% | 100,0% | Fructose intolerance, hereditary, 229600 |
| ALG1 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Ik, 608540 |
| ALG10 | 100,0% | 100,0% | No OMIM Disease ID |
| ALG11 | 96,8% | 96,8% | Congenital disorder of glycosylation, type Ip, 613661 |
| ALG12 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Ig, 607143 |
| ALG13 | 100,0% | 99,9% | Developmental and epileptic encephalopathy 36, 300884 |
| ALG14 | 100,0% | 100,0% | Intellectual developmental disorder with epilepsy, behavioral abnormalities, and coarse facies, 619031 Myopathy, epilepsy, and progressive cerebral atrophy, 619036 ?Myasthenic syndrome, congenital, 15, without tubular aggregates, 616227 |
| ALG2 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Ii, 607906 Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 |
| ALG3 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Id, 601110 |
| ALG6 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Ic, 603147 |
| ALG8 | 96,6% | 96,6% | Congenital disorder of glycosylation, type Ih, 608104 Polycystic liver disease 3 with or without kidney cysts, 617874 |
| ALG9 | 100,0% | 100,0% | Gillessen-Kaesbach-Nishimura syndrome, 263210 Congenital disorder of glycosylation, type II, 608776 |
| ALOX12B | 100,0% | 100,0% | Ichthyosis, congenital, autosomal recessive 2, 242100 |
| ALPL | 100,0% | 100,0% | Odontohypophosphatasia, 146300 Hypophosphatasia, infantile, 241500 Hypophosphatasia, childhood, 241510 Hypophosphatasia, adult, 146300 |
| AMACR | 100,0% | 100,0% | Alpha-methylacyl-CoA racemase deficiency, 614307 Bile acid synthesis defect, congenital, 4, 214950 |
| AMN | 100,0% | 100,0% | Imerslund-Grasbeck syndrome 2, 618882 |
| AMPD1 | 100,0% | 100,0% | Myopathy due to myoadenylate deaminase deficiency, 615511 |
| AMPD3 | 100,0% | 100,0% | No OMIM Disease ID |
| AMT | 100,0% | 100,0% | Glycine encephalopathy, 605899 |
| AP1S1 | 100,0% | 100,0% | MEDNIK syndrome, 609313 |
| AP3B2 | 100,0% | 99,7% | Developmental and epileptic encephalopathy 48, 617276 |
| APOA5 | 100,0% | 100,0% | Hyperchylomicronemia, late-onset, 144650 |
| APOC2 | 100,0% | 100,0% | Hyperlipoproteinemia, type Ib, 207750 |

| | | | |
|----------|--------|--------|--|
| APRT | 100,0% | 100,0% | Adenine phosphoribosyltransferase deficiency, 614723 |
| ARG1 | 92,9% | 92,9% | Argininemia, 207800 |
| ARSA | 100,0% | 100,0% | Metachromatic leukodystrophy, 250100 |
| ARSB | 100,0% | 100,0% | Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 |
| ASAH1 | 100,0% | 100,0% | Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 Farber lipogranulomatosis, 228000 |
| ASL | 100,0% | 100,0% | Argininosuccinic aciduria, 207900 |
| ASNS | 100,0% | 100,0% | Asparagine synthetase deficiency, 615574 |
| ASPA | 100,0% | 100,0% | Canavan disease, 271900 |
| ASS1 | 100,0% | 100,0% | Citrullinemia, 215700 |
| ATIC | 100,0% | 100,0% | AICA-ribosiduria due to ATIC deficiency, 608688 |
| ATP1A1 | 100,0% | 100,0% | Hypomagnesemia, seizures, and mental retardation 2, 618314 Charcot-Marie-Tooth disease, axonal, type 2DD, 618036 |
| ATP6AP1 | 100,0% | 100,0% | Immunodeficiency 47, 300972 |
| ATP6AP2 | 100,0% | 100,0% | Intellectual developmental disorder, X-linked, syndromic, Hedera type, 300423 ?Parkinsonism with spasticity, X-linked, 300911 Congenital disorder of glycosylation, type IIr, 301045 |
| ATP6VOA2 | 100,0% | 100,0% | Wrinkly skin syndrome, 278250 Cutis laxa, autosomal recessive, type IIA, 219200 |
| ATP6V1A | 100,0% | 100,0% | Cutis laxa, autosomal recessive, type IID, 617403 Developmental and epileptic encephalopathy 93, 618012 |
| ATP6V1E1 | 100,0% | 100,0% | Cutis laxa, autosomal recessive, type IIC, 617402 |
| ATP7A | 100,0% | 100,0% | Occipital horn syndrome, 304150 Spinal muscular atrophy, distal, X-linked 3, 300489 Menkes disease, 309400 |
| ATP7B | 100,0% | 100,0% | Wilson disease, 277900 |
| ATP8B1 | 100,0% | 100,0% | Cholestasis, progressive familial intrahepatic 1, 211600 Cholestasis, intrahepatic, of pregnancy, 1, 147480 Cholestasis, benign recurrent intrahepatic, 243300 |
| AUH | 100,0% | 100,0% | 3-methylglutaconic aciduria, type I, 250950 |
| B3GALNT1 | 100,0% | 100,0% | No OMIM Disease ID |
| B3GALNT2 | 92,5% | 92,5% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, 615181 |
| B3GALT6 | 99,8% | 98,8% | Ehlers-Danlos syndrome, spondylodysplastic type, 2, 615349 Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 Al-Gazali syndrome, 609465 |
| B3GAT3 | 96,2% | 94,9% | Multiple joint dislocations, short stature, craniofacial dysmorphism, with or without congenital heart defects, 245600 |
| B3GLCT | 100,0% | 100,0% | Peters-plus syndrome, 261540 |

| | | | |
|-----------|--------|--------|---|
| B4GALT1 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IId, 607091 |
| B4GALT7 | 100,0% | 100,0% | Ehlers-Danlos syndrome, spondylodysplastic type, 1, 130070 |
| B4GAT1 | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287 |
| BAAT | 100,0% | 100,0% | Bile acid conjugation defect 1, 619232 |
| BCAT1 | 100,0% | 100,0% | No OMIM Disease ID |
| BCAT2 | 100,0% | 100,0% | ?Hypervalinemia or hyperleucine-isoleucinemia, 618850 |
| BCKDHA | 100,0% | 100,0% | Maple syrup urine disease, type Ia, 248600 |
| BCKDHB | 100,0% | 100,0% | Maple syrup urine disease, type Ib, 248600 |
| BCKDK | 100,0% | 100,0% | Branched-chain keto acid dehydrogenase kinase deficiency, 614923 |
| BCO1 | 100,0% | 100,0% | ?Hypercarotenemia and vitamin A deficiency, autosomal dominant, 115300 |
| BLVRA | 100,0% | 100,0% | Hyperbiliverdinemia, 614156 |
| BMP2 | 100,0% | 100,0% | Short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies 1, 617877 Brachydactyly, type A2, 112600 |
| BPGM | 100,0% | 100,0% | Erythrocytosis, familial, 8, 222800 |
| IMPAD1 | 100,0% | 100,0% | Chondrodysplasia with joint dislocations, GPAPP type, 614078 |
| BSCL2 | 100,0% | 100,0% | Lipodystrophy, congenital generalized, type 2, 269700 Neuropathy, distal hereditary motor, type VC, 619112 Silver spastic paraplegia syndrome, 270685 Encephalopathy, progressive, with or without lipodystrophy, 615924 |
| BTD | 83,1% | 83,1% | Biotinidase deficiency, 253260 |
| C1GALT1C1 | 100,0% | 100,0% | Tn polyagglutination syndrome, somatic, 300622 |
| C2orf69 | 100,0% | 100,0% | Combined oxidative phosphorylation deficiency 53, 619423 |
| CA5A | 87,7% | 87,7% | Hyperammonemia due to carbonic anhydrase VA deficiency, 615751 |
| CAD | 100,0% | 100,0% | Developmental and epileptic encephalopathy 50, 616457 |
| CANT1 | 100,0% | 100,0% | Desbuquois dysplasia 1, 251450 Epiphyseal dysplasia, multiple, 7, 617719 |
| CAT | 100,0% | 100,0% | Acatasemia, 614097 |
| CAV1 | 100,0% | 100,0% | ?Lipodystrophy, congenital generalized, type 3, 612526 Pulmonary hypertension, primary, 3, 615343 Lipodystrophy, familial partial, type 7, 606721 |
| CAVIN1 | 100,0% | 100,0% | Lipodystrophy, congenital generalized, type 4, 613327 |
| CBLIF | 100,0% | 100,0% | Intrinsic factor deficiency, 261000 |
| CBS | 100,0% | 100,0% | Thrombosis, hyperhomocysteinemic, 236200 Homocystinuria, B6-responsive and nonresponsive types, 236200 |
| CCDC115 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Ilo, 616828 |
| CD320 | 100,0% | 100,0% | Methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 |
| CEL | 100,0% | 99,9% | Maturity-onset diabetes of the young, type VIII, 609812 |

| | | | |
|--------|--------|--------|--|
| CERKL | 100,0% | 100,0% | Retinitis pigmentosa 26, 608380 |
| CERS3 | 100,0% | 100,0% | Ichthyosis, congenital, autosomal recessive 9, 615023 |
| CFTR | 100,0% | 100,0% | Cystic fibrosis, 219700 Congenital bilateral absence of vas deferens, 277180 Sweat chloride elevation without CF, |
| CHIT1 | 100,0% | 100,0% | No OMIM Disease ID |
| CHKB | 100,0% | 100,0% | Muscular dystrophy, congenital, megaconial type, 602541 |
| CHST14 | 100,0% | 100,0% | Ehlers-Danlos syndrome, musculocontractural type 1, 601776 |
| CHST3 | 100,0% | 100,0% | Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 |
| CHST6 | 100,0% | 100,0% | Macular corneal dystrophy, 217800 |
| CHSY1 | 100,0% | 99,9% | Temtamy preaxial brachydactyly syndrome, 605282 |
| CIDEC | 100,0% | 100,0% | ?Lipodystrophy, familial partial, type 5, 615238 |
| CLCN7 | 100,0% | 100,0% | Hypopigmentation, organomegaly, and delayed myelination and development, 618541 Osteopetrosis, autosomal recessive 4, 611490 Osteopetrosis, autosomal dominant 2, 166600 |
| CLN3 | 92,7% | 92,5% | Ceroid lipofuscinosis, neuronal, 3, 204200 |
| CLN5 | 71,7% | 71,6% | Ceroid lipofuscinosis, neuronal, 5, 256731 |
| CLN6 | 100,0% | 100,0% | Ceroid lipofuscinosis, neuronal, 6B (Kufs type), 204300 Ceroid lipofuscinosis, neuronal, 6A, 601780 |
| CLN8 | 100,0% | 100,0% | Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 Ceroid lipofuscinosis, neuronal, 8, 600143 |
| CLPB | 100,0% | 100,0% | Neutropenia, severe congenital, 9, autosomal dominant, 619813 3-methylglutaconic aciduria, type VIIB, autosomal recessive, 616271 3-methylglutaconic aciduria, type VIIA, autosomal dominant, 619835 |
| CMAS | 100,0% | 100,0% | No OMIM Disease ID |
| COG1 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIg, 611209 |
| COG2 | 100,0% | 100,0% | ?Congenital disorder of glycosylation, type IIq, 617395 |
| COG4 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIj, 613489 Saul-Wilson syndrome, 618150 |
| COG5 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Ili, 613612 |
| COG6 | 100,0% | 100,0% | Shaheen syndrome, 615328 Congenital disorder of glycosylation, type III, 614576 |
| COG7 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Iie, 608779 |
| COG8 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIh, 611182 |
| COMT | 100,0% | 100,0% | No OMIM Disease ID |
| COQ2 | 97,2% | 97,2% | Coenzyme Q10 deficiency, primary, 1, 607426 |
| COQ4 | 100,0% | 100,0% | Coenzyme Q10 deficiency, primary, 7, 616276 |

| | | | |
|---------|--------|--------|---|
| COQ5 | 100,0% | 100,0% | ?Coenzyme Q10 deficiency, primary, 9, 619028 |
| COQ6 | 100,0% | 100,0% | Coenzyme Q10 deficiency, primary, 6, 614650 |
| COQ7 | 100,0% | 100,0% | ?Coenzyme Q10 deficiency, primary, 8, 616733 |
| COQ8A | 100,0% | 100,0% | Coenzyme Q10 deficiency, primary, 4, 612016 |
| COQ8B | 100,0% | 100,0% | Nephrotic syndrome, type 9, 615573 |
| COQ9 | 100,0% | 100,0% | Coenzyme Q10 deficiency, primary, 5, 614654 |
| CP | 100,0% | 100,0% | Cerebellar ataxia, 604290 Hemosiderosis, systemic, due to aceruloplasminemia, 604290 |
| CPOX | 100,0% | 100,0% | Coproporphyrinuria, 121300 Harderoporphyria, 618892 |
| CPS1 | 100,0% | 100,0% | Carbamoylphosphate synthetase I deficiency, 237300 |
| CPT1A | 100,0% | 100,0% | CPT deficiency, hepatic, type IA, 255120 |
| CPT2 | 100,0% | 100,0% | CPT II deficiency, infantile, 600649 CPT II deficiency, lethal neonatal, 608836 CPT II deficiency, myopathic, stress-induced, 255110 |
| CRAT | 100,0% | 100,0% | ?Neurodegeneration with brain iron accumulation 8, 617917 |
| CRPPA | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7, 616052 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 |
| CTH | 100,0% | 100,0% | Cystathioninuria, 219500 |
| CTNS | 100,0% | 100,0% | Cystinosis, nephropathic, 219800 Cystinosis, ocular nonnephropathic, 219750 Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 Cystinosis, atypical nephropathic, 219800 |
| CTSA | 100,0% | 100,0% | Galactosialidosis, 256540 |
| CTSC | 100,0% | 100,0% | Periodontitis 1, juvenile, 170650 Haim-Munk syndrome, 245010 Papillon-Lefevre syndrome, 245000 |
| CTSD | 100,0% | 100,0% | Ceroid lipofuscinosis, neuronal, 10, 610127 |
| CTSK | 100,0% | 100,0% | Pycnodysostosis, 265800 |
| CUBN | 100,0% | 100,0% | Imerslund-Grasbeck syndrome 1, 261100 |
| CYB561 | 100,0% | 100,0% | Orthostatic hypotension 2, 618182 |
| CYB5R3 | 100,0% | 100,0% | Methemoglobinemia, type I, 250800 Methemoglobinemia, type II, 250800 |
| CYP11A1 | 100,0% | 100,0% | Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete, 613743 |
| CYP11B1 | 100,0% | 100,0% | Aldosteronism, glucocorticoid-remediable, 103900 Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 |

| | | | |
|---------|--------|--------|--|
| CYP11B2 | 100,0% | 100,0% | Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 Aldosterone to renin ratio raised, |
| CYP17A1 | 100,0% | 100,0% | 17,20-lyase deficiency, isolated, 202110 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 |
| CYP19A1 | 100,0% | 100,0% | Aromatase deficiency, 613546 Aromatase excess syndrome, 139300 |
| CYP1B1 | 100,0% | 100,0% | Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 Anterior segment dysgenesis 6, multiple subtypes, 617315 |
| CYP21A2 | 100,0% | 100,0% | Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 |
| CYP27A1 | 100,0% | 100,0% | Cerebrotendinous xanthomatosis, 213700 |
| CYP27B1 | 100,0% | 100,0% | Vitamin D-dependent rickets, type I, 264700 |
| CYP2R1 | 100,0% | 100,0% | Rickets due to defect in vitamin D 25-hydroxylation deficiency, 600081 |
| CYP2U1 | 100,0% | 100,0% | Spastic paraplegia 56, autosomal recessive, 615030 |
| CYP7B1 | 100,0% | 100,0% | Spastic paraplegia 5A, autosomal recessive, 270800 Bile acid synthesis defect, congenital, 3, 613812 |
| D2HGDH | 100,0% | 100,0% | D-2-hydroxyglutaric aciduria, 600721 |
| DAO | 100,0% | 100,0% | No OMIM Disease ID |
| DBH | 100,0% | 100,0% | Orthostatic hypotension 1, due to DBH deficiency, 223360 |
| DBT | 100,0% | 100,0% | Maple syrup urine disease, type II, 248600 |
| DCXR | 100,0% | 100,0% | No OMIM Disease ID |
| DDC | 100,0% | 100,0% | Aromatic L-amino acid decarboxylase deficiency, 608643 |
| DDHD1 | 100,0% | 100,0% | Spastic paraplegia 28, autosomal recessive, 609340 |
| DDOST | 100,0% | 100,0% | ?Congenital disorder of glycosylation, type I _r , 614507 |
| DEGS1 | 100,0% | 100,0% | Leukodystrophy, hypomyelinating, 18, 618404 |
| DGAT1 | 100,0% | 100,0% | ?Diarrhea 7, protein-losing enteropathy type, 615863 |
| DGKE | 100,0% | 100,0% | Nephrotic syndrome, type 7, 615008 |
| DGUOK | 100,0% | 100,0% | Portal hypertension, noncirrhotic, 1, 617068 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4, 617070 Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 |
| DHCR24 | 97,7% | 97,7% | Desmosterolosis, 602398 |
| DHCR7 | 100,0% | 100,0% | Smith-Lemli-Opitz syndrome, 270400 |
| DHDDS | 95,2% | 95,2% | Developmental delay and seizures with or without movement abnormalities, 617836 ?Congenital disorder of glycosylation, type 1bb, 613861 Retinitis pigmentosa 59, 613861 |
| DHFR | 100,0% | 100,0% | Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 |

| | | | |
|---------|--------|--------|---|
| DHODH | 100,0% | 100,0% | Miller syndrome, 263750 |
| DLD | 100,0% | 100,0% | Dihydrolipoamide dehydrogenase deficiency, 246900 |
| DMGDH | 100,0% | 100,0% | Dimethylglycine dehydrogenase deficiency, 605850 |
| DNAJC12 | 100,0% | 100,0% | Hyperphenylalaninemia, mild, non-BH4-deficient, 617384 |
| DNAJC19 | 100,0% | 100,0% | 3-methylglutaconic aciduria, type V, 610198 |
| DNM1L | 100,0% | 100,0% | Optic atrophy 5, 610708 Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 |
| DNM2 | 100,0% | 100,0% | Centronuclear myopathy 1, 160150 Charcot-Marie-Tooth disease, axonal type 2M, 606482 Charcot-Marie-Tooth disease, dominant intermediate B, 606482 Lethal congenital contracture syndrome 5, 615368 |
| DNMT1 | 100,0% | 99,7% | Neuropathy, hereditary sensory, type IE, 614116 Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, 604121 |
| DNMT3B | 100,0% | 100,0% | Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 Faciocapulohumeral muscular dystrophy 4, digenic, 619478 |
| DOLK | 100,0% | 100,0% | Congenital disorder of glycosylation, type Im, 610768 |
| DPAGT1 | 100,0% | 100,0% | Myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 Congenital disorder of glycosylation, type Ij, 608093 |
| DPM1 | 99,8% | 97,8% | Congenital disorder of glycosylation, type Ie, 608799 |
| DPM2 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Iu, 615042 |
| DPM3 | 100,0% | 100,0% | ?Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15, 618992 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 15, 612937 |
| DPYD | 100,0% | 100,0% | Dihydropyrimidine dehydrogenase deficiency, 274270 5-fluorouracil toxicity, 274270 |
| DPYS | 100,0% | 100,0% | Dihydropyrimidinuria, 222748 |
| DTYMK | 100,0% | 100,0% | No OMIM Disease ID |
| EBP | 100,0% | 100,0% | MEND syndrome, 300960 Chondrodysplasia punctata, X-linked dominant, 302960 |
| ECHS1 | 100,0% | 100,0% | Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency, 616277 |
| EDEM3 | 100,0% | 100,0% | Congenital disorder of glycosylation, type 2V, 619493 |
| ELOVL1 | 100,0% | 100,0% | Ichthyotic keratoderma, spasticity, hypomyelination, and dysmorphic facies, 618527 |
| ELOVL4 | 100,0% | 100,0% | Spinocerebellar ataxia 34, 133190 Stargardt disease 3, 600110 Ichthyosis, spastic quadriplegia, and mental retardation, 614457 |
| ENO3 | 100,0% | 100,0% | Glycogen storage disease XIII, 612932 |
| EOGT | 94,3% | 90,6% | Adams-Oliver syndrome 4, 615297 |
| EPG5 | 100,0% | 100,0% | Vici syndrome, 242840 |

| | | | |
|-------|--------|--------|--|
| EPHX1 | 100,0% | 100,0% | No OMIM Disease ID |
| EPHX2 | 100,0% | 100,0% | No OMIM Disease ID |
| ETFA | 100,0% | 100,0% | Glutaric acidemia IIA, 231680 |
| ETFB | 100,0% | 100,0% | Glutaric acidemia IIB, 231680 |
| ETFDH | 100,0% | 100,0% | Glutaric acidemia IIC, 231680 |
| ETHE1 | 100,0% | 100,0% | Ethylmalonic encephalopathy, 602473 |
| EXT1 | 100,0% | 100,0% | Exostoses, multiple, type 1, 133700 Chondrosarcoma, 215300 |
| EXT2 | 100,0% | 100,0% | Seizures, scoliosis, and macrocephaly syndrome, 616682 Exostoses, multiple, type 2, 133701 |
| EYA1 | 100,0% | 100,0% | Branchiotoic syndrome 1, 602588 Branchiotoic syndrome 1, with or without cataracts, 113650 Anterior segment anomalies with or without cataract, 602588 ?Otofaciocervical syndrome, 166780 |
| FA2H | 100,0% | 100,0% | Spastic paraplegia 35, autosomal recessive, 612319 |
| FAH | 100,0% | 100,0% | Tyrosinemia, type I, 276700 |
| FAR1 | 100,0% | 100,0% | Peroxisomal fatty acyl-CoA reductase 1 disorder, 616154 Cataracts, spastic paraparesis, and speech delay, 619338 |
| FBN1 | 100,0% | 100,0% | Geleophysic dysplasia 2, 614185 Weill-Marchesani syndrome 2, dominant, 608328 Ectopia lentis, familial, 129600 MASS syndrome, 604308 Marfan lipodystrophy syndrome, 616914 Acromicric dysplasia, 102370 Marfan syndrome, 154700 Stiff skin syndrome, 184900 |
| FBP1 | 93,7% | 93,7% | Fructose-1,6-bisphosphatase deficiency, 229700 |
| FBP2 | 100,0% | 100,0% | No OMIM Disease ID |
| FCSK | 100,0% | 100,0% | Congenital disorder of glycosylation with defective fucosylation 2, 618324 |
| FDFT1 | 100,0% | 100,0% | Squalene synthase deficiency, 618156 |
| FECH | 100,0% | 100,0% | Protoporphyrinemia, erythropoietic, 1, 177000 |
| FH | 100,0% | 100,0% | Leiomyomatosis and renal cell cancer, 150800 Fumarate hydratase deficiency, 606812 |
| FKRP | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5, 606612 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 |
| FKTN | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 |

| | | | |
|--------|--------|--------|---|
| | | | Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152 Cardiomyopathy, dilated, 1X, 611615 |
| FLAD1 | 100,0% | 100,0% | Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency, 255100 |
| FMO3 | 100,0% | 100,0% | Trimethylaminuria, 602079 |
| FOLR1 | 100,0% | 100,0% | Neurodegeneration due to cerebral folate transport deficiency, 613068 |
| FTCD | 100,0% | 100,0% | Glutamate formiminotransferase deficiency, 229100 |
| FUCA1 | 100,0% | 100,0% | Fucosidosis, 230000 |
| FUT2 | 100,0% | 100,0% | No OMIM Disease ID |
| FUT6 | 100,0% | 100,0% | No OMIM Disease ID |
| FUT8 | 100,0% | 100,0% | Congenital disorder of glycosylation with defective fucosylation 1, 618005 |
| G6PC | 100,0% | 100,0% | Glycogen storage disease Ia, 232200 |
| G6PC3 | 100,0% | 100,0% | Dursun syndrome, 612541 Neutropenia, severe congenital 4, autosomal recessive, 612541 |
| G6PD | 100,0% | 100,0% | Hemolytic anemia, G6PD deficient (favism), 300908 |
| GAA | 100,0% | 100,0% | Glycogen storage disease II, 232300 |
| GAD1 | 100,0% | 100,0% | Developmental and epileptic encephalopathy 89, 619124 |
| GALC | 100,0% | 100,0% | Krabbe disease, 245200 |
| GALE | 100,0% | 100,0% | Galactose epimerase deficiency, 230350 |
| GALK1 | 100,0% | 100,0% | Galactokinase deficiency with cataracts, 230200 |
| GALM | 100,0% | 100,0% | Galactosemia IV, 618881 |
| GALNS | 100,0% | 100,0% | Mucopolysaccharidosis IVA, 253000 |
| GALNT2 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIc, 618885 |
| GALNT3 | 100,0% | 100,0% | Tumoral calcinosis, hyperphosphatemic, familial, 1, 211900 |
| GALT | 100,0% | 100,0% | Galactosemia, 230400 |
| GAMT | 100,0% | 100,0% | Cerebral creatine deficiency syndrome 2, 612736 |
| GANAB | 100,0% | 100,0% | Polycystic kidney disease 3, 600666 |
| GATM | 100,0% | 100,0% | Cerebral creatine deficiency syndrome 3, 612718 Fanconi renal tubular syndrome 1, 134600 |
| GBA | 100,0% | 100,0% | Gaucher disease, type II, 230900 Gaucher disease, type IIIC, 231005 Gaucher disease, type III, 231000 Gaucher disease, type I, 230800 Gaucher disease, perinatal lethal, 608013 |
| GBA2 | 100,0% | 100,0% | Spastic paraplegia 46, autosomal recessive, 614409 |
| GBE1 | 100,0% | 100,0% | Glycogen storage disease IV, 232500 Polyglucosan body disease, adult form, 263570 |
| GCDH | 100,0% | 100,0% | Glutaricaciduria, type I, 231670 |

| | | | |
|--------|--------|--------|--|
| GCH1 | 100,0% | 100,0% | Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230 Hyperphenylalaninemia, BH4-deficient, B, 233910 |
| GCK | 97,0% | 93,1% | MODY, type II, 125851 Diabetes mellitus, permanent neonatal 1, 606176 Hyperinsulinemic hypoglycemia, familial, 3, 602485 Diabetes mellitus, noninsulin-dependent, late onset, 125853 |
| GCLC | 100,0% | 100,0% | Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 |
| GCLM | 100,0% | 100,0% | No OMIM Disease ID |
| GCSH | 100,0% | 100,0% | ?Glycine encephalopathy, 605899 |
| GFPT1 | 100,0% | 100,0% | Myasthenia, congenital, 12, with tubular aggregates, 610542 |
| GGPS1 | 100,0% | 100,0% | Muscular dystrophy, congenital hearing loss, and ovarian insufficiency syndrome, 619518 |
| GK | 100,0% | 100,0% | Glycerol kinase deficiency, 307030 |
| GLA | 91,3% | 91,3% | Fabry disease, cardiac variant, 301500 Fabry disease, 301500 |
| GLB1 | 100,0% | 100,0% | GM1-gangliosidosis, type I, 230500 GM1-gangliosidosis, type III, 230650 Mucopolysaccharidosis type IVB (Morquio), 253010 GM1-gangliosidosis, type II, 230600 |
| GLDC | 100,0% | 100,0% | Glycine encephalopathy, 605899 |
| GLRA1 | 100,0% | 100,0% | Hyperreflexia 1, 149400 |
| GLRX5 | 100,0% | 100,0% | Anemia, sideroblastic, 3, pyridoxine-refractory, 616860 Spasticity, childhood-onset, with hyperglycinemia, 616859 |
| GLS | 100,0% | 100,0% | Global developmental delay, progressive ataxia, and elevated glutamine, 618412 ?Infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development, 618339 Developmental and epileptic encephalopathy 71, 618328 |
| GLUD1 | 100,0% | 100,0% | Hyperinsulinism-hyperammonemia syndrome, 606762 |
| GLUL | 100,0% | 100,0% | Glutamine deficiency, congenital, 610015 |
| GLYCTK | 100,0% | 100,0% | D-glyceric aciduria, 220120 |
| GM2A | 100,0% | 100,0% | GM2-gangliosidosis, AB variant, 272750 |
| GMPPA | 100,0% | 100,0% | Alacrima, achalasia, and mental retardation syndrome, 615510 |
| GMPPB | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, 615351 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 |
| GMPS | 100,0% | 100,0% | No OMIM Disease ID |
| GNE | 100,0% | 100,0% | Sialuria, 269921 Nonaka myopathy, 605820 |
| GNMT | 100,0% | 100,0% | Glycine N-methyltransferase deficiency, 606664 |

| | | | |
|---------|--------|--------|--|
| GNPAT | 100,0% | 100,0% | Rhizomelic chondrodysplasia punctata, type 2, 222765 |
| GNPTAB | 100,0% | 100,0% | Mucopolipidosis III alpha/beta, 252600 Mucopolipidosis II alpha/beta, 252500 |
| GNPTG | 100,0% | 100,0% | Mucopolipidosis III gamma, 252605 |
| GNS | 100,0% | 100,0% | Mucopolysaccharidosis type IIID, 252940 |
| GOT1 | 100,0% | 100,0% | Aspartate aminotransferase, serum level of, QTL1, 614419 |
| GOT2 | 100,0% | 100,0% | Developmental and epileptic encephalopathy 82, 618721 |
| GPD1 | 100,0% | 100,0% | Hypertriglyceridemia, transient infantile, 614480 |
| GPD1L | 100,0% | 100,0% | Brugada syndrome 2, 611777 |
| GPHN | 100,0% | 100,0% | Molybdenum cofactor deficiency C, 615501 |
| GPI | 100,0% | 100,0% | Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 |
| GPIHBP1 | 100,0% | 100,0% | Hyperlipoproteinemia, type 1D, 615947 |
| GPT2 | 100,0% | 100,0% | Neurodevelopmental disorder with microcephaly and spastic paraplegia, 616281 |
| GPX1 | 100,0% | 100,0% | No OMIM Disease ID |
| GRHPR | 100,0% | 99,9% | Hyperoxaluria, primary, type II, 260000 |
| GSS | 100,0% | 100,0% | Hemolytic anemia due to glutathione synthetase deficiency, 231900 Glutathione synthetase deficiency, 266130 |
| GUSB | 100,0% | 100,0% | Mucopolysaccharidosis VII, 253220 |
| GYG1 | 100,0% | 100,0% | ?Glycogen storage disease XV, 613507 Polyglucosan body myopathy 2, 616199 |
| GYS1 | 100,0% | 100,0% | Glycogen storage disease 0, muscle, 611556 |
| GYS2 | 100,0% | 100,0% | Glycogen storage disease 0, liver, 240600 |
| H6PD | 100,0% | 100,0% | Cortisone reductase deficiency 1, 604931 |
| HADH | 100,0% | 100,0% | Hyperinsulinemic hypoglycemia, familial, 4, 609975 3-hydroxyacyl-CoA dehydrogenase deficiency, 231530 |
| HADHA | 100,0% | 100,0% | HELLP syndrome, maternal, of pregnancy, 609016 Mitochondrial trifunctional protein deficiency, 609015 LCHAD deficiency, 609016 Fatty liver, acute, of pregnancy, 609016 |
| HADHB | 100,0% | 100,0% | Trifunctional protein deficiency, 609015 |
| HAGH | 100,0% | 99,7% | No OMIM Disease ID |
| HEXA | 100,0% | 100,0% | GM2-gangliosidosis, several forms, 272800 Tay-Sachs disease, 272800 |
| HEXB | 100,0% | 100,0% | Sandhoff disease, infantile, juvenile, and adult forms, 268800 |
| HFE | 100,0% | 100,0% | Hemochromatosis, 235200 |
| HGD | 100,0% | 100,0% | Alkaptonuria, 203500 |

| | | | |
|----------|--------|--------|---|
| HGSNAT | 92,1% | 92,1% | Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 Retinitis pigmentosa 73, 616544 |
| HIBADH | 100,0% | 100,0% | No OMIM Disease ID |
| HIBCH | 100,0% | 100,0% | 3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 |
| HK1 | 100,0% | 100,0% | Retinitis pigmentosa 79, 617460 Neuropathy, hereditary motor and sensory, Russe type, 605285 Neurodevelopmental disorder with visual defects and brain anomalies, 618547 Hemolytic anemia due to hexokinase deficiency, 235700 |
| HLCS | 100,0% | 100,0% | Holocarboxylase synthetase deficiency, 253270 |
| HMBS | 100,0% | 100,0% | Porphyria, acute intermittent, nonerythroid variant, 176000 Porphyria, acute intermittent, 176000 |
| HMGCL | 100,0% | 100,0% | HMG-CoA lyase deficiency, 246450 |
| HMGCS2 | 100,0% | 100,0% | HMG-CoA synthase-2 deficiency, 605911 |
| HMOX1 | 100,0% | 100,0% | Heme oxygenase-1 deficiency, 614034 |
| HNF1A | 100,0% | 100,0% | Hepatic adenoma, somatic, 142330 Diabetes mellitus, insulin-dependent, 20, 612520 MODY, type III, 600496 Renal cell carcinoma, 144700 |
| HNF4A | 100,0% | 100,0% | Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 MODY, type I, 125850 |
| HOGA1 | 100,0% | 100,0% | Hyperoxaluria, primary, type III, 613616 |
| HPD | 100,0% | 100,0% | Hawkinsinuria, 140350 Tyrosinemia, type III, 276710 |
| HPDL | 100,0% | 100,0% | Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities, 619026 Spastic paraplegia 83, autosomal recessive, 619027 |
| HPRT1 | 100,0% | 100,0% | Hyperuricemia, HRPT-related, 300323 Lesch-Nyhan syndrome, 300322 |
| HS6ST1 | 100,0% | 100,0% | No OMIM Disease ID |
| HSD11B1 | 100,0% | 100,0% | Cortisone reductase deficiency 2, 614662 |
| HSD11B2 | 100,0% | 100,0% | Apparent mineralocorticoid excess, 218030 |
| HSD17B10 | 100,0% | 100,0% | HSD10 mitochondrial disease, 300438 |
| HSD17B3 | 99,0% | 99,0% | Pseudohermaphroditism, male, with gynecomastia, 264300 |
| HSD17B4 | 96,6% | 96,6% | D-bifunctional protein deficiency, 261515 Perrault syndrome 1, 233400 |
| HSD3B2 | 100,0% | 100,0% | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency, 201810 |
| HSD3B7 | 100,0% | 100,0% | Bile acid synthesis defect, congenital, 1, 607765 |
| HTRA2 | 100,0% | 100,0% | 3-methylglutaconic aciduria, type VIII, 617248 |

| | | | |
|--------|--------|--------|---|
| HYAL1 | 100,0% | 100,0% | Mucopolysaccharidosis type IX, 601492 |
| IDH2 | 100,0% | 100,0% | D-2-hydroxyglutaric aciduria 2, 613657 |
| IDH3B | 100,0% | 100,0% | Retinitis pigmentosa 46, 612572 |
| IDI1 | 100,0% | 100,0% | No OMIM Disease ID |
| IDS | 100,0% | 100,0% | Mucopolysaccharidosis II, 309900 |
| IDUA | 100,0% | 100,0% | Mucopolysaccharidosis Is, 607016 Mucopolysaccharidosis Ih/s, 607015 Mucopolysaccharidosis Ih, 607014 |
| IMPDH1 | 100,0% | 100,0% | Retinitis pigmentosa 10, 180105 Leber congenital amaurosis 11, 613837 |
| INPP5E | 100,0% | 100,0% | Joubert syndrome 1, 213300 Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 |
| INPPL1 | 100,0% | 100,0% | Opsismodysplasia, 258480 |
| INSR | 100,0% | 100,0% | Rabson-Mendenhall syndrome, 262190 Leprechaunism, 246200 Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 Hyperinsulinemic hypoglycemia, familial, 5, 609968 |
| IREB2 | 100,0% | 100,0% | Neurodegeneration, early-onset, with choreoathetoid movements and microcytic anemia, 618451 |
| ITCH | 95,6% | 93,9% | Autoimmune disease, multisystem, with facial dysmorphism, 613385 |
| ITPA | 100,0% | 100,0% | Developmental and epileptic encephalopathy 35, 616647 |
| IVD | 100,0% | 100,0% | Isovaleric acidemia, 243500 |
| KCNA2 | 100,0% | 100,0% | Developmental and epileptic encephalopathy 32, 616366 |
| KCNJ11 | 100,0% | 100,0% | Diabetes, permanent neonatal 2, with or without neurologic features, 618856 Maturity-onset diabetes of the young, type 13, 616329 Diabetes mellitus, transient neonatal 3, 610582 Hyperinsulinemic hypoglycemia, familial, 2, 601820 |
| KMT2A | 100,0% | 100,0% | Wiedemann-Steiner syndrome, 605130 |
| KMT2D | 100,0% | 100,0% | Kabuki syndrome 1, 147920 |
| L2HGDH | 100,0% | 100,0% | L-2-hydroxyglutaric aciduria, 236792 |
| LAMP2 | 100,0% | 100,0% | Danon disease, 300257 |
| LARGE1 | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6, 608840 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154 |
| LCAT | 100,0% | 100,0% | Fish-eye disease, 136120 Norum disease, 245900 |
| LCT | 100,0% | 100,0% | Lactase deficiency, congenital, 223000 |
| LDHA | 100,0% | 100,0% | Glycogen storage disease XI, 612933 |
| LDHB | 100,0% | 100,0% | No OMIM Disease ID |

| | | | |
|--------|--------|--------|---|
| LFNG | 99,3% | 96,6% | Spondylocostal dysostosis 3, autosomal recessive, 609813 |
| LIAS | 100,0% | 100,0% | Hyperglycinemia, lactic acidosis, and seizures, 614462 |
| LIPA | 95,2% | 95,2% | Wolman disease, 278000 Cholesteryl ester storage disease, 278000 |
| LIPC | 100,0% | 100,0% | Hepatic lipase deficiency, 614025 |
| LIPE | 100,0% | 100,0% | Lipodystrophy, familial partial, type 6, 615980 |
| LIPT1 | 100,0% | 100,0% | Lipoyltransferase 1 deficiency, 616299 |
| LIPT2 | 100,0% | 100,0% | Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities, 617668 |
| LMBRD1 | 96,1% | 96,1% | Methylmalonic aciduria and homocystinuria, cb1F type, 277380 |
| LMF1 | 100,0% | 100,0% | Lipase deficiency, combined, 246650 |
| LMNA | 100,0% | 100,0% | Mandibuloacral dysplasia, 248370 Heart-hand syndrome, Slovenian type, 610140 Cardiomyopathy, dilated, 1A, 115200 Emery-Dreifuss muscular dystrophy 3, autosomal recessive, 616516 Restrictive dermopathy 2, 619793 Charcot-Marie-Tooth disease, type 2B1, 605588 Emery-Dreifuss muscular dystrophy 2, autosomal dominant, 181350 Hutchinson-Gilford progeria, 176670 Lipodystrophy, familial partial, type 2, 151660 Muscular dystrophy, congenital, 613205 Malouf syndrome, 212112 |
| LMNB2 | 100,0% | 99,8% | Microcephaly 27, primary, autosomal dominant, 619180 ?Epilepsy, progressive myoclonic, 9, 616540 |
| LPIN1 | 100,0% | 100,0% | Myoglobinuria, acute recurrent, autosomal recessive, 268200 |
| LPIN2 | 100,0% | 100,0% | Majeed syndrome, 609628 |
| LPL | 100,0% | 100,0% | Lipoprotein lipase deficiency, 238600 Combined hyperlipidemia, familial, 144250 |
| LRAT | 100,0% | 100,0% | Leber congenital amaurosis 14, 613341 Retinal dystrophy, early-onset severe, 613341 Retinitis pigmentosa, juvenile, 613341 |
| LTC4S | 100,0% | 100,0% | No OMIM Disease ID |
| LYST | 100,0% | 100,0% | Chediak-Higashi syndrome, 214500 |
| MAN1B1 | 100,0% | 100,0% | Rafiq syndrome, 614202 |
| MAN2B1 | 100,0% | 100,0% | Mannosidosis, alpha-, types I and II, 248500 |
| MAN2B2 | 100,0% | 100,0% | No OMIM Disease ID |
| MANBA | 100,0% | 100,0% | Mannosidosis, beta, 248510 |
| MAOA | 99,9% | 99,4% | Brunner syndrome, 300615 |

| | | | |
|--------|--------|--------|--|
| MAT1A | 100,0% | 100,0% | Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 Methionine adenosyltransferase deficiency, autosomal recessive, 250850 |
| MBOAT7 | 100,0% | 100,0% | Intellectual developmental disorder, autosomal recessive 57, 617188 |
| MCCC1 | 100,0% | 100,0% | 3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 |
| MCCC2 | 100,0% | 100,0% | 3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 |
| MCEE | 100,0% | 100,0% | Methylmalonyl-CoA epimerase deficiency, 251120 |
| MCOLN1 | 100,0% | 100,0% | Mucopolidosis IV, 252650 |
| MDH1 | 100,0% | 100,0% | ?Developmental and epileptic encephalopathy 88, 618959 |
| MFSD2A | 100,0% | 100,0% | Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain abnormalities, 616486 |
| MFSD8 | 100,0% | 100,0% | Macular dystrophy with central cone involvement, 616170 Ceroid lipofuscinosis, neuronal, 7, 610951 |
| MGAT2 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIa, 212066 |
| MINPP1 | 100,0% | 100,0% | Pontocerebellar hypoplasia, type 16, 619527 |
| MLYCD | 100,0% | 100,0% | Malonyl-CoA decarboxylase deficiency, 248360 |
| MMAA | 100,0% | 100,0% | Methylmalonic aciduria, vitamin B12-responsive, cblA type, 251100 |
| MMAB | 100,0% | 100,0% | Methylmalonic aciduria, vitamin B12-responsive, cblB type, 251110 |
| MMACHC | 100,0% | 100,0% | Methylmalonic aciduria and homocystinuria, cblC type, 277400 |
| MMADHC | 89,7% | 89,7% | Methylmalonic aciduria, cblD type, variant 2, 277410 Methylmalonic aciduria and homocystinuria, cblD type, 277410 Homocystinuria, cblD type, variant 1, 277410 |
| MMUT | 100,0% | 100,0% | Methylmalonic aciduria, mut(0) type, 251000 |
| MOCOS | 100,0% | 100,0% | Xanthinuria, type II, 603592 |
| MOCS1 | 100,0% | 100,0% | Molybdenum cofactor deficiency A, 252150 |
| MOCS2 | 100,0% | 100,0% | Molybdenum cofactor deficiency B, 252160 |
| MOGS | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIb, 606056 |
| MORC2 | 100,0% | 100,0% | Charcot-Marie-Tooth disease, axonal, type 2Z, 616688 Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy, 619090 |
| MPDU1 | 100,0% | 100,0% | Congenital disorder of glycosylation, type If, 609180 |
| MPI | 100,0% | 100,0% | Congenital disorder of glycosylation, type Ib, 602579 |
| MRPL44 | 100,0% | 100,0% | Combined oxidative phosphorylation deficiency 16, 615395 |
| MRPS36 | 100,0% | 100,0% | No OMIM Disease ID |
| MSMO1 | 100,0% | 100,0% | Microcephaly, congenital cataract, and psoriasiform dermatitis, 616834 |
| MTHFD1 | 100,0% | 100,0% | Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia, 617780 |
| MTHFR | 100,0% | 100,0% | Homocystinuria due to MTHFR deficiency, 236250 |
| MTM1 | 100,0% | 100,0% | Myopathy, centronuclear, X-linked, 310400 |
| MTMR2 | 100,0% | 100,0% | Charcot-Marie-Tooth disease, type 4B1, 601382 |
| MTR | 100,0% | 100,0% | Homocystinuria-megaloblastic anemia, cblG complementation type, 250940 |

| | | | |
|--------|--------|--------|---|
| MTRR | 100,0% | 100,0% | Homocystinuria-megaloblastic anemia, cbl E type, 236270 |
| MVK | 90,5% | 90,5% | Hyper-IgD syndrome, 260920 Porokeratosis 3, multiple types, 175900 Mevalonic aciduria, 610377 |
| NADK2 | 100,0% | 100,0% | 2,4-dienoyl-CoA reductase deficiency, 616034 |
| NAGA | 100,0% | 100,0% | Schindler disease, type I, 609241 Kanzaki disease, 609242 Schindler disease, type III, 609241 |
| NAGLU | 100,0% | 100,0% | ?Charcot-Marie-Tooth disease, axonal, type 2V, 616491 Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 |
| NAGS | 100,0% | 100,0% | N-acetylglutamate synthase deficiency, 237310 |
| NANS | 100,0% | 100,0% | Spondyloepimetaphyseal dysplasia, Camera-Genevieve type, 610442 |
| NAXD | 100,0% | 100,0% | Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2, 618321 |
| NAXE | 100,0% | 100,0% | Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 |
| NBAS | 100,0% | 100,0% | Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 Infantile liver failure syndrome 2, 616483 |
| NEU1 | 100,0% | 100,0% | Sialidosis, type II, 256550 Sialidosis, type I, 256550 |
| NGLY1 | 100,0% | 100,0% | Congenital disorder of deglycosylation 1, 615273 |
| NMNAT1 | 100,0% | 98,5% | Spondyloepiphyseal dysplasia, sensorineural hearing loss, intellectual developmental disorder, and Leber congenital amaurosis, 619260 Leber congenital amaurosis 9, 608553 |
| NNT | 96,4% | 96,4% | Glucocorticoid deficiency 4, with or without mineralocorticoid deficiency, 614736 |
| NPC1 | 100,0% | 100,0% | Niemann-Pick disease, type C1, 257220 Niemann-Pick disease, type D, 257220 |
| NPC2 | 100,0% | 100,0% | Niemann-pick disease, type C2, 607625 |
| NPL | 100,0% | 100,0% | No OMIM Disease ID |
| NSD1 | 100,0% | 100,0% | Sotos syndrome, 117550 |
| NSDHL | 100,0% | 100,0% | CK syndrome, 300831 CHILD syndrome, 308050 |
| NT5C3A | 100,0% | 100,0% | Anemia, hemolytic, due to UMPH1 deficiency, 266120 |
| NT5E | 100,0% | 100,0% | Calcification of joints and arteries, 211800 |
| NUS1 | 100,0% | 100,0% | Intellectual developmental disorder, autosomal dominant 55, with seizures, 617831 ?Congenital disorder of glycosylation, type 1aa, 617082 |
| OAT | 100,0% | 100,0% | Gyrate atrophy of choroid and retina with or without ornithinemia, 258870 |
| OCRL | 100,0% | 100,0% | Dent disease 2, 300555 Lowe syndrome, 309000 |

| | | | |
|--------|--------|--------|---|
| ODC1 | 100,0% | 100,0% | Bachmann-Bupp syndrome, 619075 |
| OGDH | 100,0% | 100,0% | ?Oxoglutarate dehydrogenase deficiency, 203740 |
| OGDHL | 100,0% | 100,0% | Yoon-Bellen neurodevelopmental syndrome, 619701 |
| OPA3 | 100,0% | 100,0% | 3-methylglutaconic aciduria, type III, 258501 Optic atrophy 3 with cataract, 165300 |
| OPLAH | 100,0% | 100,0% | 5-oxoprolinase deficiency, 260005 |
| OTC | 100,0% | 100,0% | Ornithine transcarbamylase deficiency, 311250 |
| OXCT1 | 100,0% | 100,0% | Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 |
| PAH | 100,0% | 100,0% | Phenylketonuria, 261600 |
| PANK2 | 100,0% | 100,0% | HARP syndrome, 607236 Neurodegeneration with brain iron accumulation 1, 234200 |
| PC | 100,0% | 100,0% | Pyruvate carboxylase deficiency, 266150 |
| PCBD1 | 100,0% | 100,0% | Hyperphenylalaninemia, BH4-deficient, D, 264070 |
| PCCA | 100,0% | 100,0% | Propionicacidemia, 606054 |
| PCCB | 99,9% | 98,1% | Propionicacidemia, 606054 |
| PCK1 | 100,0% | 100,0% | ?Phosphoenolpyruvate carboxykinase deficiency, cytosolic, 261680 |
| PCK2 | 100,0% | 100,0% | No OMIM Disease ID |
| PCYT1A | 100,0% | 100,0% | Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 |
| PCYT2 | 100,0% | 100,0% | Spastic paraplegia 82, autosomal recessive, 618770 |
| PDSS1 | 97,4% | 97,4% | Coenzyme Q10 deficiency, primary, 2, 614651 |
| PDSS2 | 100,0% | 100,0% | Coenzyme Q10 deficiency, primary, 3, 614652 |
| PEPD | 100,0% | 100,0% | Prolidase deficiency, 170100 |
| PEX1 | 100,0% | 100,0% | Heimler syndrome 1, 234580 Peroxisome biogenesis disorder 1B (NALD/IRD), 601539 Peroxisome biogenesis disorder 1A (Zellweger), 214100 |
| PEX10 | 100,0% | 100,0% | Peroxisome biogenesis disorder 6A (Zellweger), 614870 Peroxisome biogenesis disorder 6B, 614871 |
| PEX11B | 100,0% | 100,0% | Peroxisome biogenesis disorder 14B, 614920 |
| PEX12 | 100,0% | 100,0% | Peroxisome biogenesis disorder 3B, 266510 Peroxisome biogenesis disorder 3A (Zellweger), 614859 |
| PEX13 | 100,0% | 100,0% | Peroxisome biogenesis disorder 11A (Zellweger), 614883 Peroxisome biogenesis disorder 11B, 614885 |
| PEX14 | 100,0% | 100,0% | Peroxisome biogenesis disorder 13A (Zellweger), 614887 |
| PEX16 | 100,0% | 100,0% | Peroxisome biogenesis disorder 8B, 614877 Peroxisome biogenesis disorder 8A (Zellweger), 614876 |
| PEX19 | 100,0% | 100,0% | Peroxisome biogenesis disorder 12A (Zellweger), 614886 |

| | | | |
|--------|--------|--------|--|
| PEX2 | 100,0% | 100,0% | Peroxisome biogenesis disorder 5A (Zellweger), 614866 Peroxisome biogenesis disorder 5B, 614867 |
| PEX26 | 100,0% | 100,0% | Peroxisome biogenesis disorder 7B, 614873 Peroxisome biogenesis disorder 7A (Zellweger), 614872 |
| PEX3 | 100,0% | 100,0% | Peroxisome biogenesis disorder 10A (Zellweger), 614882 ?Peroxisome biogenesis disorder 10B, 617370 |
| PEX5 | 100,0% | 100,0% | Peroxisome biogenesis disorder 2B, 202370 Peroxisome biogenesis disorder 2A (Zellweger), 214110 Rhizomelic chondrodysplasia punctata, type 5, 616716 |
| PEX6 | 100,0% | 100,0% | Peroxisome biogenesis disorder 4B, 614863 Peroxisome biogenesis disorder 4A (Zellweger), 614862 Heimler syndrome 2, 616617 |
| PEX7 | 91,3% | 91,3% | Rhizomelic chondrodysplasia punctata, type 1, 215100 Peroxisome biogenesis disorder 9B, 614879 |
| PFKM | 100,0% | 100,0% | Glycogen storage disease VII, 232800 |
| PGAM2 | 100,0% | 100,0% | Glycogen storage disease X, 261670 |
| PGAP1 | 100,0% | 100,0% | Neurodevelopmental disorder with dysmorphic features, spasticity, and brain abnormalities, 615802 |
| PGAP2 | 100,0% | 100,0% | Hyperphosphatasia with mental retardation syndrome 3, 614207 |
| PGAP3 | 100,0% | 100,0% | Hyperphosphatasia with mental retardation syndrome 4, 615716 |
| PGK1 | 100,0% | 100,0% | Phosphoglycerate kinase 1 deficiency, 300653 |
| PGM1 | 94,2% | 94,2% | Congenital disorder of glycosylation, type It, 614921 |
| PGM2L1 | 100,0% | 100,0% | No OMIM Disease ID |
| PGM3 | 91,7% | 91,7% | Immunodeficiency 23, 615816 |
| PHGDH | 100,0% | 100,0% | Neu-Laxova syndrome 1, 256520 Phosphoglycerate dehydrogenase deficiency, 601815 |
| PHKA1 | 100,0% | 99,9% | Muscle glycogenosis, 300559 |
| PHKA2 | 100,0% | 100,0% | Glycogen storage disease, type IXa2, 306000 Glycogen storage disease, type IXa1, 306000 |
| PHKB | 100,0% | 100,0% | Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 |
| PHKG1 | 100,0% | 100,0% | No OMIM Disease ID |
| PHKG2 | 100,0% | 100,0% | Glycogen storage disease IXc, 613027 |
| PHYH | 100,0% | 100,0% | Refsum disease, 266500 |
| PI4K2A | 100,0% | 100,0% | No OMIM Disease ID |
| PIGA | 100,0% | 100,0% | Paroxysmal nocturnal hemoglobinuria, somatic, 300818 Multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 Neurodevelopmental disorder with epilepsy and hemochromatosis, 301072 |
| PIGB | 100,0% | 100,0% | Developmental and epileptic encephalopathy 80, 618580 |

| | | | |
|---------|--------|--------|--|
| PIGC | 100,0% | 100,0% | Glycosylphosphatidylinositol biosynthesis defect 16, 617816 |
| PIGL | 100,0% | 100,0% | CHIME syndrome, 280000 |
| PIGM | 100,0% | 100,0% | Glycosylphosphatidylinositol deficiency, 610293 |
| PIGN | 98,8% | 98,8% | Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 |
| PIGO | 100,0% | 100,0% | Hyperphosphatasia with mental retardation syndrome 2, 614749 |
| PIGP | 100,0% | 100,0% | Developmental and epileptic encephalopathy 55, 617599 |
| PIGQ | 100,0% | 100,0% | Multiple congenital anomalies-hypotonia-seizures syndrome 4, 618548 |
| PIGT | 100,0% | 100,0% | ?Paroxysmal nocturnal hemoglobinuria 2, 615399 Multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398 |
| PIGV | 100,0% | 100,0% | Hyperphosphatasia with mental retardation syndrome 1, 239300 |
| PIGW | 100,0% | 100,0% | Glycosylphosphatidylinositol biosynthesis defect 11, 616025 |
| PIGY | 100,0% | 100,0% | Hyperphosphatasia with mental retardation syndrome 6, 616809 |
| PIK3CA | 100,0% | 100,0% | CLOVE syndrome, somatic, 612918 Hepatocellular carcinoma, somatic, 114550 Breast cancer, somatic, 114480 Ovarian cancer, somatic, 167000 Colorectal cancer, somatic, 114500 CLAPO syndrome, somatic, 613089 Keratosis, seborrheic, somatic, 182000 Nevus, epidermal, somatic, 162900 Gastric cancer, somatic, 613659 Nonsmall cell lung cancer, somatic, 211980 Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 Cowden syndrome 5, 615108 Macrodactyly, somatic,, |
| PIK3R1 | 100,0% | 100,0% | Immunodeficiency 36, 616005 ?Agammaglobulinemia 7, autosomal recessive, 615214 SHORT syndrome, 269880 |
| PIK3R2 | 100,0% | 100,0% | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 |
| PIK3R5 | 100,0% | 100,0% | Ataxia-oculomotor apraxia 3, 615217 |
| PIKFYVE | 100,0% | 100,0% | Corneal fleck dystrophy, 121850 |
| PIP5K1C | 100,0% | 100,0% | Lethal congenital contractural syndrome 3, 611369 |
| PKLR | 100,0% | 100,0% | Adenosine triphosphate, elevated, of erythrocytes, 102900 Pyruvate kinase deficiency, 266200 |
| PLA2G5 | 100,0% | 100,0% | No OMIM Disease ID |
| PLA2G6 | 92,3% | 92,3% | Parkinson disease 14, autosomal recessive, 612953 Neurodegeneration with brain iron accumulation 2B, 610217 Infantile neuroaxonal dystrophy 1, 256600 |

| | | | |
|---------|--------|--------|--|
| PLA2G7 | 100,0% | 100,0% | Platelet-activating factor acetylhydrolase deficiency, 614278 |
| PLCB1 | 100,0% | 100,0% | Developmental and epileptic encephalopathy 12, 613722 |
| PLCB4 | 100,0% | 100,0% | Auriculocondylar syndrome 2, 614669 |
| PLCD1 | 100,0% | 100,0% | Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 |
| PLCE1 | 100,0% | 100,0% | Nephrotic syndrome, type 3, 610725 |
| PLCG2 | 100,0% | 100,0% | Autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 Familial cold autoinflammatory syndrome 3, 614468 |
| PLIN1 | 100,0% | 100,0% | Lipodystrophy, familial partial, type 4, 613877 |
| PLOD1 | 100,0% | 100,0% | Ehlers-Danlos syndrome, kyphoscoliotic type, 1, 225400 |
| PLOD2 | 100,0% | 100,0% | Bruck syndrome 2, 609220 |
| PLOD3 | 100,0% | 100,0% | Lysyl hydroxylase 3 deficiency, 612394 |
| PLPBP | 100,0% | 100,0% | Epilepsy, early-onset, vitamin B6-dependent, 617290 |
| PMM2 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Ia, 212065 |
| PNLIP | 100,0% | 100,0% | ?Pancreatic lipase deficiency, 614338 |
| PNMT | 100,0% | 100,0% | No OMIM Disease ID |
| PNP | 100,0% | 100,0% | Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 |
| PNPLA2 | 100,0% | 100,0% | Neutral lipid storage disease with myopathy, 610717 |
| PNPLA6 | 100,0% | 100,0% | Spastic paraplegia 39, autosomal recessive, 612020 Oliver-McFarlane syndrome, 275400 ?Laurence-Moon syndrome, 245800 Boucher-Neuhauser syndrome, 215470 |
| PNPO | 100,0% | 100,0% | Pyridoxamine 5'-phosphate oxidase deficiency, 610090 |
| POFUT1 | 100,0% | 100,0% | Dowling-Degos disease 2, 615327 |
| POGLUT1 | 100,0% | 100,0% | Dowling-Degos disease 4, 615696 ?Muscular dystrophy, limb-girdle, autosomal recessive 21, 617232 |
| POLD1 | 100,0% | 100,0% | Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 |
| POLR3A | 100,0% | 100,0% | Wiedemann-Rautenstrauch syndrome, 264090 Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 |
| POLR3B | 100,0% | 100,0% | Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 Charcot-Marie-Tooth disease, demyelinating, type 1I, 619742 |
| POMGNT1 | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157 Retinitis pigmentosa 76, 617123 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 |
| POMGNT2 | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (limb-girdle) type C, 8, 618135 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 8, 614830 |

| | | | |
|--------|--------|--------|---|
| POMK | 100,0% | 100,0% | ?Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 12, 616094 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249 |
| POMT1 | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155 |
| POMT2 | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 |
| PPARG | 98,3% | 98,3% | Insulin resistance, severe, digenic, 604367 Lipodystrophy, familial partial, type 3, 604367 Obesity, severe, 601665 Carotid intimal medial thickness 1, 609338 |
| PPCS | 100,0% | 100,0% | Cardiomyopathy, dilated, 2C, 618189 |
| PPM1K | 100,0% | 100,0% | ?Maple syrup urine disease, mild variant, 615135 |
| PPOX | 100,0% | 100,0% | Porphyria variegata, 176200 |
| PPT1 | 82,5% | 82,5% | Ceroid lipofuscinosis, neuronal, 1, 256730 |
| PRKAG2 | 100,0% | 99,9% | Glycogen storage disease of heart, lethal congenital, 261740 Wolff-Parkinson-White syndrome, 194200 Cardiomyopathy, hypertrophic 6, 600858 |
| PRKCSH | 100,0% | 100,0% | Polycystic liver disease 1, 174050 |
| PRODH | 100,0% | 100,0% | Hyperprolinemia, type I, 239500 |
| PRPS1 | 100,0% | 100,0% | Arts syndrome, 301835 Phosphoribosylpyrophosphate synthetase superactivity, 300661 Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070 Deafness, X-linked 1, 304500 Gout, PRPS-related, 300661 |
| PSAP | 100,0% | 100,0% | Combined SAP deficiency, 611721 Krabbe disease, atypical, 611722 Metachromatic leukodystrophy due to SAP-b deficiency, 249900 Gaucher disease, atypical, 610539 |
| PSAT1 | 100,0% | 100,0% | Neu-Laxova syndrome 2, 616038 ?Phosphoserine aminotransferase deficiency, 610992 |
| PSPH | 100,0% | 100,0% | Phosphoserine phosphatase deficiency, 614023 |
| PTEN | 100,0% | 100,0% | Cowden syndrome 1, 158350 Lhermitte-Duclos disease, 158350 Prostate cancer, somatic, 176807 Macrocephaly/autism syndrome, 605309 |
| PTGIS | 100,0% | 100,0% | Hypertension, essential, 145500 |

| | | | |
|----------|--------|--------|---|
| PTPN11 | 100,0% | 100,0% | Noonan syndrome 1, 163950 LEOPARD syndrome 1, 151100 Metachondromatosis, 156250 Leukemia, juvenile myelomonocytic, somatic, 607785 |
| PTS | 100,0% | 100,0% | Hyperphenylalaninemia, BH4-deficient, A, 261640 |
| PUS3 | 100,0% | 100,0% | Neurodevelopmental disorder with microcephaly and gray sclerae, 617051 |
| PYCR1 | 100,0% | 100,0% | Cutis laxa, autosomal recessive, type IIIB, 614438 Cutis laxa, autosomal recessive, type IIB, 612940 |
| PYCR2 | 100,0% | 100,0% | Leukodystrophy, hypomyelinating, 10, 616420 |
| PYGL | 100,0% | 100,0% | Glycogen storage disease VI, 232700 |
| PYGM | 100,0% | 100,0% | McArdle disease, 232600 |
| QDPR | 100,0% | 100,0% | Hyperphenylalaninemia, BH4-deficient, C, 261630 |
| RBCK1 | 100,0% | 100,0% | Polyglucosan body myopathy 1 with or without immunodeficiency, 615895 |
| RDH12 | 100,0% | 100,0% | Leber congenital amaurosis 13, 612712 |
| RDH5 | 100,0% | 100,0% | Fundus albipunctatus, 136880 |
| RFT1 | 100,0% | 100,0% | Congenital disorder of glycosylation, type In, 612015 |
| RINT1 | 100,0% | 100,0% | Infantile liver failure syndrome 3, 618641 |
| RPE65 | 100,0% | 100,0% | Retinitis pigmentosa 20, 613794 Retinitis pigmentosa 87 with choroidal involvement, 618697 Leber congenital amaurosis 2, 204100 |
| RPIA | 100,0% | 100,0% | Ribose 5-phosphate isomerase deficiency, 608611 |
| RPN2 | 100,0% | 100,0% | No OMIM Disease ID |
| RXYLT1 | 100,0% | 100,0% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 |
| SARDH | 91,4% | 91,4% | No OMIM Disease ID |
| SAT1 | 100,0% | 100,0% | No OMIM Disease ID |
| SC5D | 100,0% | 100,0% | Lathosterolosis, 607330 |
| SCARB2 | 100,0% | 100,0% | Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 |
| SCP2 | 100,0% | 100,0% | ?Leukoencephalopathy with dystonia and motor neuropathy, 613724 |
| SCYL1 | 100,0% | 100,0% | Spinocerebellar ataxia, autosomal recessive 21, 616719 |
| SEC23B | 100,0% | 100,0% | ?Cowden syndrome 7, 616858 Dyserythropoietic anemia, congenital, type II, 224100 |
| SELENBP1 | 100,0% | 100,0% | Extraoral halitosis due to MTO deficiency, 618148 |
| SEPSECS | 100,0% | 100,0% | Pontocerebellar hypoplasia type 2D, 613811 |
| SERAC1 | 100,0% | 100,0% | 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 |
| SGSH | 100,0% | 100,0% | Mucopolysaccharidosis type IIIA (Sanfilippo A), 252900 |
| SI | 100,0% | 100,0% | Sucrase-isomaltase deficiency, congenital, 222900 |
| SLC10A7 | 100,0% | 100,0% | Short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 |

| | | | |
|----------|--------|--------|---|
| SLC12A1 | 96,2% | 96,2% | Bartter syndrome, type 1, 601678 |
| SLC13A3 | 100,0% | 100,0% | Leukoencephalopathy, acute reversible, with increased urinary alpha-ketoglutarate, 618384 |
| SLC16A1 | 100,0% | 100,0% | Hyperinsulinemic hypoglycemia, familial, 7, 610021 Erythrocyte lactate transporter defect, 245340 Monocarboxylate transporter 1 deficiency, 616095 |
| SLC17A5 | 100,0% | 100,0% | Salla disease, 604369 Sialic acid storage disorder, infantile, 269920 |
| SLC18A2 | 100,0% | 100,0% | ?Parkinsonism-dystonia, infantile, 2, 618049 |
| SLC22A12 | 100,0% | 100,0% | Hypouricemia, renal, 220150 |
| SLC22A5 | 100,0% | 100,0% | Carnitine deficiency, systemic primary, 212140 |
| SLC25A1 | 100,0% | 100,0% | Combined D-2- and L-2-hydroxyglutaric aciduria, 615182 Myasthenic syndrome, congenital, 23, presynaptic, 618197 |
| SLC25A13 | 100,0% | 100,0% | Citrullinemia, type II, neonatal-onset, 605814 Citrullinemia, adult-onset type II, 603471 |
| SLC25A15 | 100,0% | 100,0% | Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 |
| SLC25A19 | 100,0% | 100,0% | Microcephaly, Amish type, 607196 Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 |
| SLC25A20 | 100,0% | 100,0% | Carnitine-acylcarnitine translocase deficiency, 212138 |
| SLC25A21 | 100,0% | 100,0% | ?Mitochondrial DNA depletion syndrome 18, 618811 |
| SLC25A32 | 100,0% | 100,0% | ?Exercise intolerance, riboflavin-responsive, 616839 |
| SLC25A38 | 100,0% | 100,0% | Anemia, sideroblastic, 2, pyridoxine-refractory, 205950 |
| SLC25A42 | 100,0% | 100,0% | Metabolic crises, recurrent, with variable encephalomyopathic features and neurologic regression, 618416 |
| SLC28A1 | 100,0% | 100,0% | No OMIM Disease ID |
| SLC2A1 | 100,0% | 100,0% | Dystonia 9, 601042 GLUT1 deficiency syndrome 1, infantile onset, severe, 606777 Stomatin-deficient cryohydrocytosis with neurologic defects, 608885 GLUT1 deficiency syndrome 2, childhood onset, 612126 |
| SLC2A2 | 100,0% | 100,0% | Fanconi-Bickel syndrome, 227810 |
| SLC2A9 | 100,0% | 100,0% | Hypouricemia, renal, 2, 612076 |
| SLC30A10 | 100,0% | 100,0% | Hypermanganesemia with dystonia 1, 613280 |
| SLC33A1 | 100,0% | 100,0% | Spastic paraplegia 42, autosomal dominant, 612539 Congenital cataracts, hearing loss, and neurodegeneration, 614482 |
| SLC35A1 | 100,0% | 100,0% | Congenital disorder of glycosylation, type II _f , 603585 |
| SLC35A2 | 100,0% | 100,0% | Congenital disorder of glycosylation, type II _m , 300896 |
| SLC35A3 | 81,0% | 81,0% | Arthrogryposis, impaired intellectual development, and seizures, 615553 |
| SLC35C1 | 100,0% | 100,0% | Congenital disorder of glycosylation, type II _c , 266265 |
| SLC35D1 | 100,0% | 100,0% | Schneckenbecken dysplasia, 269250 |

| | | | |
|----------|--------|--------|--|
| SLC37A4 | 100,0% | 100,0% | Glycogen storage disease Ib, 232220 Congenital disorder of glycosylation, type IIw, 619525 Glycogen storage disease Ic, 232240 |
| SLC39A14 | 93,6% | 93,5% | ?Hyperostosis cranialis interna, 144755 Hypermanganesemia with dystonia 2, 617013 |
| SLC39A4 | 100,0% | 100,0% | Acrodermatitis enteropathica, 201100 |
| SLC39A8 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIh, 616721 |
| SLC3A1 | 96,6% | 96,6% | Cystinuria, 220100 |
| SLC44A1 | 100,0% | 100,0% | Neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline, 618868 |
| SLC46A1 | 100,0% | 100,0% | Folate malabsorption, hereditary, 229050 |
| SLC52A1 | 100,0% | 100,0% | Riboflavin deficiency, 615026 |
| SLC52A2 | 100,0% | 100,0% | Brown-Vialetto-Van Laere syndrome 2, 614707 |
| SLC52A3 | 100,0% | 100,0% | ?Fazio-Londe disease, 211500 Brown-Vialetto-Van Laere syndrome 1, 211530 |
| SLC5A1 | 100,0% | 100,0% | Glucose/galactose malabsorption, 606824 |
| SLC5A2 | 100,0% | 100,0% | Renal glucosuria, 233100 |
| SLC6A19 | 100,0% | 100,0% | Iminoglycinuria, digenic, 242600 Hartnup disorder, 234500 Hyperglycinuria, 138500 |
| SLC6A5 | 100,0% | 100,0% | Hyperekplexia 3, 614618 |
| SLC6A8 | 100,0% | 100,0% | Cerebral creatine deficiency syndrome 1, 300352 |
| SLC6A9 | 100,0% | 100,0% | Glycine encephalopathy with normal serum glycine, 617301 |
| SLC7A7 | 100,0% | 100,0% | Lysinuric protein intolerance, 222700 |
| SLC7A9 | 100,0% | 100,0% | Cystinuria, 220100 |
| SLCO1B1 | 99,9% | 99,9% | Hyperbilirubinemia, Rotor type, digenic, 237450 |
| SLCO1B3 | 100,0% | 100,0% | Hyperbilirubinemia, Rotor type, digenic, 237450 |
| SMPD1 | 100,0% | 100,0% | Niemann-Pick disease, type B, 607616 Niemann-Pick disease, type A, 257200 |
| SMS | 100,0% | 100,0% | Intellectual developmental disorder, X-linked syndromic, Snyder-Robinson type, 309583 |
| SNX14 | 100,0% | 100,0% | Spinocerebellar ataxia, autosomal recessive 20, 616354 |
| SOD1 | 100,0% | 100,0% | Spastic tetraplegia and axial hypotonia, progressive, 618598 Amyotrophic lateral sclerosis 1, 105400 |
| SOD2 | 100,0% | 100,0% | No OMIM Disease ID |
| SPR | 100,0% | 100,0% | Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 |
| SPTLC1 | 100,0% | 100,0% | Neuropathy, hereditary sensory and autonomic, type IA, 162400 |
| SPTLC2 | 100,0% | 100,0% | Neuropathy, hereditary sensory and autonomic, type IC, 613640 |
| SQOR | 100,0% | 100,0% | Sulfide:quinone oxidoreductase deficiency, 619221 |

| | | | |
|----------|--------|--------|--|
| SRD5A2 | 100,0% | 100,0% | Pseudovaginal perineoscrotal hypospadias, 264600 |
| SRD5A3 | 100,0% | 100,0% | Kahrizi syndrome, 612713 Congenital disorder of glycosylation, type Iq, 612379 |
| SSR4 | 100,0% | 100,0% | Congenital disorder of glycosylation, type Iy, 300934 |
| ST3GAL3 | 95,8% | 95,2% | Developmental and epileptic encephalopathy 15, 615006 Intellectual developmental disorder, autosomal recessive 12, 611090 |
| ST3GAL5 | 98,7% | 98,7% | Salt and pepper developmental regression syndrome, 609056 |
| STAR | 100,0% | 100,0% | Lipoid adrenal hyperplasia, 201710 |
| STS | 97,4% | 97,3% | Ichthyosis, X-linked, 308100 |
| STT3A | 100,0% | 100,0% | Congenital disorder of glycosylation, type Iw, autosomal dominant, 619714 Congenital disorder of glycosylation, type Iw, autosomal recessive, 615596 |
| STT3B | 100,0% | 100,0% | ?Congenital disorder of glycosylation, type Ix, 615597 |
| STX5 | 100,0% | 100,0% | No OMIM Disease ID |
| SUCLA2 | 100,0% | 99,9% | Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 |
| SUCLG1 | 100,0% | 100,0% | Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 |
| SUCLG2 | 100,0% | 100,0% | No OMIM Disease ID |
| SUGCT | 100,0% | 100,0% | Glutaric aciduria III, 231690 |
| SUMF1 | 100,0% | 100,0% | Multiple sulfatase deficiency, 272200 |
| SUOX | 100,0% | 100,0% | Sulfite oxidase deficiency, 272300 |
| TAZ | 100,0% | 100,0% | Barth syndrome, 302060 |
| TALDO1 | 100,0% | 100,0% | Transaldolase deficiency, 606003 |
| TANGO2 | 100,0% | 100,0% | Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration, 616878 |
| TAT | 100,0% | 100,0% | Tyrosinemia, type II, 276600 |
| TBXAS1 | 100,0% | 100,0% | Ghosal hematodiaphyseal syndrome, 231095 |
| TCIRG1 | 100,0% | 100,0% | Osteopetrosis, autosomal recessive 1, 259700 |
| TCN2 | 100,0% | 100,0% | Transcobalamin II deficiency, 275350 |
| TECR | 100,0% | 100,0% | Intellectual developmental disorder, autosomal recessive 14, 614020 |
| TH | 100,0% | 100,0% | Segawa syndrome, recessive, 605407 |
| TIMM50 | 100,0% | 100,0% | 3-methylglutaconic aciduria, type IX, 617698 |
| TK2 | 100,0% | 100,0% | Mitochondrial DNA depletion syndrome 2 (myopathic type), 609560 ?Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3, 617069 |
| TKFC | 100,0% | 100,0% | Triokinase and FMN cyclase deficiency syndrome, 618805 |
| TKT | 98,8% | 98,7% | Short stature, developmental delay, and congenital heart defects, 617044 |
| TMEM106B | 100,0% | 100,0% | Leukodystrophy, hypomyelinating, 16, 617964 |
| TMEM165 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIk, 614727 |
| TMEM199 | 100,0% | 100,0% | Congenital disorder of glycosylation, type IIp, 616829 |

| | | | |
|----------|--------|--------|--|
| TMEM70 | 100,0% | 100,0% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 |
| TMLHE | 99,6% | 99,5% | No OMIM Disease ID |
| TPI1 | 100,0% | 100,0% | Hemolytic anemia due to triosephosphate isomerase deficiency, 615512 |
| TPK1 | 100,0% | 100,0% | Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 |
| TPMT | 100,0% | 100,0% | No OMIM Disease ID |
| TPP1 | 100,0% | 100,0% | Ceroid lipofuscinosis, neuronal, 2, 204500 Spinocerebellar ataxia, autosomal recessive 7, 609270 |
| TRAK1 | 100,0% | 100,0% | Developmental and epileptic encephalopathy 68, 618201 |
| TRAPPC11 | 100,0% | 100,0% | Muscular dystrophy, limb-girdle, autosomal recessive 18, 615356 |
| TRAPPC2L | 100,0% | 100,0% | Encephalopathy, progressive, early-onset, with episodic rhabdomyolysis, 618331 |
| TREH | 100,0% | 100,0% | Trehalase deficiency, 612119 |
| TUSC3 | 100,0% | 100,0% | Intellectual developmental disorder, autosomal recessive 7, 611093 |
| TYMP | 100,0% | 100,0% | Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 |
| TYMS | 100,0% | 100,0% | No OMIM Disease ID |
| TYR | 100,0% | 100,0% | Albinism, oculocutaneous, type IB, 606952 Waardenburg syndrome/albinism, digenic, 103470 Albinism, oculocutaneous, type IA, 203100 |
| TYRP1 | 100,0% | 100,0% | Albinism, oculocutaneous, type III, 203290 |
| UFM1 | 100,0% | 100,0% | Leukodystrophy, hypomyelinating, 14, 617899 |
| UGT1A1 | 100,0% | 100,0% | Crigler-Najjar syndrome, type I, 218800 Hyperbilirubinemia, familial transient neonatal, 237900 Crigler-Najjar syndrome, type II, 606785 |
| UMPS | 97,0% | 97,0% | Orotic aciduria, 258900 |
| UPB1 | 100,0% | 100,0% | Beta-ureidopropionase deficiency, 613161 |
| UROC1 | 100,0% | 100,0% | ?Urocanase deficiency, 276880 |
| UROD | 100,0% | 100,0% | Porphyria, hepatoerythropoietic, 176100 Porphyria cutanea tarda, 176100 |
| UROS | 100,0% | 100,0% | Porphyria, congenital erythropoietic, 263700 |
| VMA21 | 100,0% | 100,0% | Myopathy, X-linked, with excessive autophagy, 310440 |
| VPS13B | 99,5% | 99,4% | Cohen syndrome, 216550 |
| VPS33A | 89,9% | 89,9% | Mucopolysaccharidosis-plus syndrome, 617303 |
| XDH | 100,0% | 100,0% | Xanthinuria, type I, 278300 |
| XYLT1 | 100,0% | 99,7% | Desbuquois dysplasia 2, 615777 |
| XYLT2 | 96,7% | 96,7% | Spondyloocular syndrome, 605822 |
| ZBTB11 | 100,0% | 100,0% | Intellectual developmental disorder, autosomal recessive 69, 618383 |
| ZMPSTE24 | 100,0% | 100,0% | Mandibuloacral dysplasia with type B lipodystrophy, 608612 Restrictive dermopathy 1, 275210 |

Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

TWIST is the chemistry used for WES analysis.

Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x.

Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x.

Genes with coverage denoting NC are non-protein coding genes.

non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : April 19th , 2022.

This list is accurate for panel version DG 3.4.0

Ad 1. "No OMIM Disease ID" signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors
